Detalhe da pesquisa
1.
Alirocumab and Lipid Levels, Inflammatory Biomarkers, Metabolomics, and Safety in Patients Receiving Maintenance Dialysis: The ALIrocumab in DIALysis Study (A Phase 3 Trial to Evaluate the Efficacy and Safety of Biweekly Alirocumab in Patients on a Stable Dialysis Regimen).
Kidney Med
; 4(7): 100483, 2022 Jul.
Artigo
Inglês
| MEDLINE | ID: mdl-35801187